Editas Medicine Inc [NASDAQ: EDIT] traded at a high on Wednesday, posting a 0.52 gain after which it closed the day’ session at $3.88.
The results of the trading session contributed to over 3099877 shares changing hands. Over the past one week, the price volatility of Editas Medicine Inc stands at 5.65% while the volatility over the past one month is 5.55%.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The market cap for EDIT stock reached $320.02 million, with 81.77 million shares outstanding and 81.70 million shares in the current float. Compared to the average trading volume of 1.85M shares, EDIT reached a trading volume of 3099877 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Editas Medicine Inc [EDIT]?
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for EDIT shares is $13.80 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on EDIT stock is a recommendation set at 2.05. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
BofA Securities have made an estimate for Editas Medicine Inc shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 08, 2024. The new note on the price target was released on May 09, 2024, representing the official price target for Editas Medicine Inc stock. Previously, the target price had yet another raise to $11, while Citigroup analysts kept a Buy rating on EDIT stock.
The Average True Range (ATR) for Editas Medicine Inc is set at 0.23, with the Price to Sales ratio for EDIT stock in the period of the last 12 months amounting to 4.77. The Price to Book ratio for the last quarter was 1.38, with the Price to Cash per share for the same quarter was set at 3.38.
How has EDIT stock performed recently?
Editas Medicine Inc [EDIT] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 2.65. With this latest performance, EDIT shares dropped by -5.37% in over the last four-week period, additionally sinking by -49.94% over the last 6 months – not to mention a drop of -51.56% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for EDIT stock in for the last two-week period is set at 47.84, with the RSI for the last a single of trading hit 53.92, and the three-weeks RSI is set at 45.02 for Editas Medicine Inc [EDIT]. The present Moving Average for the last 50 days of trading for this stock 4.44, while it was recorded at 3.85 for the last single week of trading, and 6.62 for the last 200 days.
Editas Medicine Inc [EDIT]: Deeper insight into the fundamentals
Editas Medicine Inc’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.85 and a Current Ratio set at 3.85.
Earnings analysis for Editas Medicine Inc [EDIT]
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for EDIT. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Editas Medicine Inc go to 1.70%.
Insider trade positions for Editas Medicine Inc [EDIT]
There are presently around $71.58%, or 71.81%% of EDIT stock, in the hands of institutional investors. The top three institutional holders of EDIT stocks are: VANGUARD GROUP INC with ownership of 8.03 million shares, which is approximately 9.8032%. BLACKROCK INC., holding 7.78 million shares of the stock with an approximate value of $$36.34 million in EDIT stocks shares; and BLACKROCK INC., currently with $$28.02 million in EDIT stock with ownership which is approximately 7.3225%.
